Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer

Ya Gao, Shuzhen Shi, Ming Liu, Fanqi Wu, Junhua Zhang, Fujian Song, Jinhui Tian

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the efficacy and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide compared with platinum-etoposide alone for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

Original languageEnglish
Article numberCD014809
JournalCochrane Database of Systematic Reviews
Volume2021
Issue number10
DOIs
Publication statusPublished - 19 Oct 2021

Cite this